MedTrace Logo

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

NCT01962896 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if the combination of an mTOR inhibitor (sirolimus) with an EGFR inhibitor (erlotinib) is effective at treating relapsed or refractory germ cell tumors, and to find out what the side-effects of this regimen are.

Conditions

  • Relapsed / Recurrent Germ Cell Tumors

Interventions

DRUG

Erlotinib

DRUG

Sirolimus

Sponsors & Collaborators

  • Theodore Laetsch

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-08
Primary Completion
2017-06-13
Completion
2018-01-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962896 on ClinicalTrials.gov